ZA200604723B - Agents for preventing and/or treating higher brain dysfunctions - Google Patents
Agents for preventing and/or treating higher brain dysfunctionsInfo
- Publication number
- ZA200604723B ZA200604723B ZA200604723A ZA200604723A ZA200604723B ZA 200604723 B ZA200604723 B ZA 200604723B ZA 200604723 A ZA200604723 A ZA 200604723A ZA 200604723 A ZA200604723 A ZA 200604723A ZA 200604723 B ZA200604723 B ZA 200604723B
- Authority
- ZA
- South Africa
- Prior art keywords
- agents
- preventing
- higher brain
- brain dysfunctions
- treating higher
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/12—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1, 3, and 7, e.g. caffeine
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003410432 | 2003-12-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200604723B true ZA200604723B (en) | 2009-11-25 |
Family
ID=34674933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200604723A ZA200604723B (en) | 2003-12-09 | 2006-06-08 | Agents for preventing and/or treating higher brain dysfunctions |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20070078148A1 (pt) |
| EP (1) | EP1709966A4 (pt) |
| JP (1) | JPWO2005056016A1 (pt) |
| KR (1) | KR20060124615A (pt) |
| CN (1) | CN1889959A (pt) |
| AU (1) | AU2004296137A1 (pt) |
| BR (1) | BRPI0417241A (pt) |
| CA (1) | CA2550130A1 (pt) |
| WO (1) | WO2005056016A1 (pt) |
| ZA (1) | ZA200604723B (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9101580B2 (en) | 2012-12-18 | 2015-08-11 | Matthew Bennett | Compositions and methods for treating traumatic brain injury |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4755517A (en) * | 1986-07-31 | 1988-07-05 | Warner-Lambert Company | Derivatives of xanthine, pharmaceutical compositions and methods of use therefor |
| GB8906792D0 (en) * | 1989-03-23 | 1989-05-10 | Beecham Wuelfing Gmbh & Co Kg | Treatment and compounds |
| FR2665636B1 (fr) * | 1990-08-10 | 1994-10-07 | Adir | Utilisation d'un derive de la trimethyl-1,3,7 xanthine pour le traitement des troubles de la memoire, des troubles intellectuels de la senescence et de la maladie d'alzheimer. |
| JPH08512281A (ja) * | 1993-02-26 | 1996-12-24 | メレル ダウ ファーマス−ティカルズ インコーポレイテッド | アデノシンａ▲下１▼受容体拮抗剤としてのキサンチン誘導体類 |
| US5703085A (en) * | 1994-02-23 | 1997-12-30 | Kyowa Hakko Kogyo Co., Ltd. | Xanthine derivatives |
| ATE325610T1 (de) * | 1997-09-05 | 2006-06-15 | Kyowa Hakko Kogyo Kk | Xanthinderivative zur behandlung von hirnischämie |
| WO2002089736A2 (en) * | 2001-05-08 | 2002-11-14 | Blanchette Rockefeller Neurosciences Institute | Adenosine a1 receptor antagonists for treating hypoxia-induced learning and memory impairment |
| AR056615A1 (es) * | 2002-12-27 | 2007-10-17 | Kyowa Hakko Kogyo Kk | Un metodo de tratamiento de trastornos de la conducta |
-
2004
- 2004-12-09 AU AU2004296137A patent/AU2004296137A1/en not_active Abandoned
- 2004-12-09 CA CA002550130A patent/CA2550130A1/en not_active Abandoned
- 2004-12-09 WO PCT/JP2004/018765 patent/WO2005056016A1/ja active Application Filing
- 2004-12-09 BR BRPI0417241-8A patent/BRPI0417241A/pt not_active IP Right Cessation
- 2004-12-09 KR KR1020067011123A patent/KR20060124615A/ko not_active Application Discontinuation
- 2004-12-09 US US10/579,829 patent/US20070078148A1/en not_active Abandoned
- 2004-12-09 EP EP04807124A patent/EP1709966A4/en not_active Withdrawn
- 2004-12-09 JP JP2005516245A patent/JPWO2005056016A1/ja active Pending
- 2004-12-09 CN CNA2004800362670A patent/CN1889959A/zh active Pending
-
2006
- 2006-06-08 ZA ZA200604723A patent/ZA200604723B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2005056016A1 (ja) | 2007-07-05 |
| AU2004296137A1 (en) | 2005-06-23 |
| EP1709966A4 (en) | 2009-04-29 |
| US20070078148A1 (en) | 2007-04-05 |
| CN1889959A (zh) | 2007-01-03 |
| KR20060124615A (ko) | 2006-12-05 |
| CA2550130A1 (en) | 2005-06-23 |
| WO2005056016A1 (ja) | 2005-06-23 |
| EP1709966A1 (en) | 2006-10-11 |
| BRPI0417241A (pt) | 2007-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1701767A4 (en) | STIMULATION FOR THE TREATMENT AND DIAGNOSIS OF TREATMENTS | |
| EP1636359A4 (en) | METHODS OF TREATING PAIN | |
| EP1683067A4 (en) | METHOD FOR THE INVESTIGATION AND TREATMENT OF DISEASES | |
| HK1089676A1 (en) | Formulations and methods for treating rhinosinusitis | |
| IL208191A0 (en) | Compositions and methods for treating rage-associated disorders | |
| EP1689485A4 (en) | CARDIOELECTROMAGNETIC TREATMENT | |
| EP1680009A4 (en) | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF MENTAL ILLNESSES | |
| EP1696877A4 (en) | PROCESS FOR PAIN TREATMENT | |
| IL164219A0 (en) | Method for treating and preventing hyparathyroidism | |
| HUS1300035I1 (hu) | Dihidroimidazolonok alkalmazása epilepszia kezelésére kutyákban | |
| GB0326486D0 (en) | Combination treatment | |
| EP1567198A4 (en) | MATERIALS AND METHOD FOR THE TREATMENT OF EYE DISEASES | |
| EP1677794A4 (en) | METHODS OF TREATING DISORDERS | |
| AU2003268032A8 (en) | Composition and methods for treatment and screening | |
| GB0312407D0 (en) | Treatment | |
| HUP0303264A3 (en) | Carbamate compounds for use in preventing and treating neurodegenerative disorders | |
| EP1409015A4 (en) | METHODS OF TREATING OR PREVENTING SKIN DISORDERS USING CD2 BINDING AGENTS | |
| GB2425617B (en) | Device for preventing and treating myopia | |
| EP1635801A4 (en) | METHODS OF TREATMENT AND PREVENTION OF CARDIAC ARRHYTHMIA | |
| HUP0303261A3 (en) | Carbamate compounds for use in preventing or treating bipolar disorder | |
| EP1840948A4 (en) | FINE TREATMENT AGENT AND FINE TREATMENT METHOD USING THE SAME | |
| AU2003249181A8 (en) | Methods for treating or preventing ischemic injury | |
| HUP0303243A3 (en) | Carbamate compounds for use in preventing and treating bipolar disorder | |
| EP1663283A4 (en) | GLUTAMINE FOR THE TREATMENT OF LESION | |
| IL175579A0 (en) | Epithelium treatment methods and devices for treating the epithelium |